We are live on ! Find out more
APLS

Apellis Pharmaceuticals
APLS

Delisted

APLS was delisted on the 13th of May, 2026.

Back to rankings

46 hedge funds and large institutions have $340M invested in Apellis Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 46 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

31.29% more ownership

Funds ownership: 0% → 31.29% (+31%)

Holders
46
Holders Change
+46
Holders Change %
–
% of All Funds
1.04%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.09%
New
46
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
+$55.5M
2
SAM
Sectoral Asset Management
Quebec, Canada
+$25.8M
3
VC
Vivo Capital
California
+$21.5M
4
HIM
Hillhouse Investment Management
Cayman Islands
+$21M
5
EC
EcoR1 Capital
California
+$16.8M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$81.8M +$55.5M +3,768,757 New
SAM
2
Sectoral Asset Management
Quebec, Canada
$38M +$25.8M +1,752,655 New
VC
3
Vivo Capital
California
$31.6M +$21.5M +1,457,834 New
HIM
4
Hillhouse Investment Management
Cayman Islands
$31M +$21M +1,428,571 New
EC
5
EcoR1 Capital
California
$24.8M +$16.8M +1,144,558 New
BlackRock
6
BlackRock
New York
$21.1M +$14.3M +972,152 New
CCP
7
Clough Capital Partners
Massachusetts
$19.7M +$13.5M +917,116 New
RCM
8
RA Capital Management
Massachusetts
$19.5M +$13.2M +900,000 New
Jennison Associates
9
Jennison Associates
New York
$13.2M +$8.93M +606,925 New
DM
10
Deerfield Management
New York
$11.1M +$7.55M +513,000 New
NTC
11
NF Trinity Capital
Hong Kong
$7.75M +$5.26M +357,142 New
ACA
12
Avoro Capital Advisors
New York
$7.32M +$5.84M +396,635 New
Fidelity Investments
13
Fidelity Investments
Massachusetts
$6.59M +$4.47M +303,917 New
Vanguard Group
14
Vanguard Group
Pennsylvania
$5.95M +$4.03M +274,074 New
Geode Capital Management
15
Geode Capital Management
Massachusetts
$3.17M +$2.15M +146,195 New
CS
16
Candriam SCA
Luxembourg
$2.54M +$1.72M +117,000 New
Northern Trust
17
Northern Trust
Illinois
$2.5M +$1.69M +115,127 New
State Street
18
State Street
Massachusetts
$2.08M +$1.41M +95,946 New
AllianceBernstein
19
AllianceBernstein
Tennessee
$1.84M +$1.25M +85,000 New
Norges Bank
20
Norges Bank
Norway
$1.63M +$1.1M +75,000 New
OAM
21
Oxford Asset Management
United Kingdom
$1.12M +$761K +51,670 New
LCM
22
Laurion Capital Management
New York
$1.08M +$736K +50,000 New
Charles Schwab
23
Charles Schwab
California
$863K +$585K +39,742 New
Deutsche Bank
24
Deutsche Bank
Germany
$516K +$350K +23,808 New
Bank of New York Mellon
25
Bank of New York Mellon
New York
$416K +$282K +19,166 New
1
2

APLS Hedge Fund Activity: Q4 2017 in Review

46 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q4 2017, worth a combined $340M.

Buyers outnumbered sellers: 46 funds opened new APLS positions and 0 closed out — a net gain of 46 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $55.5M.

  • 46 institutional investors held Apellis Pharmaceuticals (APLS) as of Q4 2017, up from 0 in Q3 2017.
  • Funds reported $340M of Apellis Pharmaceuticals stock for Q4 2017.
  • 46 funds opened new Apellis Pharmaceuticals positions in Q4 2017 and 0 closed out, a net change of +46 holders.
  • The largest Apellis Pharmaceuticals buyer in Q4 2017 was Cormorant Asset Management, an estimated $55.5M added.

Based on aggregated 13F filings for Q4 2017.